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Background. Gastroesophageal reflux disease (GERD) is the most frequent chronic gastrointestinal disorder. It is defined as a
condition developed when the reflux of gastric contents causes troublesome symptoms (heartburn and regurgitation). 0is
requires adequate treatment since it can lead to long-term complications including esophagus adenocarcinoma. Proton pump
inhibitors (PPI) are generally used to treat GERD due to their high-security profile and efficiency on most patients. However,
recurrent reflux despite initial treatment is frequent. N-of-1 trial is a study that allows the identification of the best treatment for
each patient. 0e objective of this study is to compare the efficacy of standard dose with double dosage of esomeprazole, to
improve the GERD symptoms in a single patient.Methods. A single-patient trial, placebo-controlled, randomized, double-blind,
was carried out from September 25th, 2012, to April 26th, 2013. It included one outpatient at the gastroenterology service in a
fourth-level hospital, diagnosed with nonerosive reflux disease (NERD). Yet, his symptoms were heartburn and reflux, and his
endoscopic results were normal esophageal mucosa, without hiatal hernia, though pathological pH values. A no-obese male
without any tobacco or alcohol usage received esomeprazole 40mg/day and 40mg/bid for 24 weeks. A standardized gastro-
esophageal reflux disease questionnaire (GerdQ) was used weekly to evaluate symptom frequency and severity. 0e consumption
of 90% of the capsules was considered as an adequate treatment adherence. D’agostino–Pearson and Wilcoxon test were used to
determine normal or nonnormal distribution and compare both treatments, respectively, both with a significant statistical
difference of p< 0.05. Results. 0e patient completed the study with 96% of adherence.0e double dosage of esomeprazole did not
improve the control of symptoms compared with the standard dosage. Mean symptomatic score was 9.5±0.5 and 10.2±0.6 for each
treatment, respectively (p> 0.05). Conclusion. 0ere was no significant improvement in the patient GERD symptoms increasing
the dose of oral esomeprazole during the 6 months of study. N-of-1 trials in chronic pathologies including GERD are rec-
ommended due to their potential value as systematic methods that evaluate therapies without strong scientific evidence.
1. Introduction
0e gastroesophageal reflux disease (GERD) is the most
frequent chronic gastrointestinal disorder in the United
States and Europe [1]. According to a recent systematic
review, its prevalence in the USA is 18.1%–27.8% [2, 3]. 0e
Montreal consensus defined GERD as a condition that
develops when the reflux of stomach contents causes
Hindawi
Canadian Journal of Gastroenterology and Hepatology
Volume 2019, Article ID 3926051, 9 pages
https://doi.org/10.1155/2019/3926051
troublesome symptoms and/or complications [4]. Heart-
burn, known as retrosternal burning, and regurgitation are
highly specific symptoms for GERD [5]; these should be
present at least weekly as they have been associated with a
clinically meaningful quality of life impairment [6]. 0is
entity requires adequate treatment since it can lead to long-
term complications such as Barrett esophagus and/or
esophagus adenocarcinoma [7].
Proton pump inhibitors (PPI) are generally used to treat
patients diagnosed with GERD due to their high-security
profile and efficiency on most of the patients [8]. However, a
recent systematic review indicates that 17–32% of the pa-
tients show recurrent reflux after the initial treatment [9];
between 10–40% of patients with GERD fail to respond
symptomatically, either partially or completely, to a stan-
dard-dose proton pump inhibitor; these usually have
functional heartburn [10]. According to several studies,
alternative therapeutic options are considered for those
patients who partially respond to the initial PPI treatment
[8, 11, 12]. 0is includes increasing the dose of PPI (i.e.,
doubling the dose), changing to a different PPI, or adding a
supplementary treatment such as the antagonists of the
histamine-2 receptors or prokinetic agents [13]. 0us, these
treatment options are not clearly established in the literature
[14]. In clinical practice, the GERD symptoms regularly
persist after the initial PPI treatment, leading physicians to
consider the use of PPI double-dose [8].
0ere is a current controversy between clinical trials and
expert opinions whether doubling PPI dosage is indeed
clinically useful when treating patients with uncontrolled
symptoms after using a standard dose treatment [15–18].
Besides, there is no strong scientific evidence that supports
such alternative for heartburn resolution in either erosive
esophagitis or nonerosive reflux disease [19]. Patients with
GERD usually require a continue therapy, either continuous,
at demand, or intermittent [20]. Additionally, GERD has
heterogeneous recurrent clinical expressions and many
patients frequently experience symptomatic setbacks, which
could be easily self-evaluated [21–23].
Several noninvasive strategies have been developed to
assess GERD symptoms, such as questionnaires. 0ese are
used as screening tools since they are low cost and can be
self-administered [3]. 0e most common questionnaires are
Carlsson–Dent, ReQuest, and GerdQ [24]. 0e GerdQ was
developed from 3 validated questionnaires that assess dif-
ferent aspects of GERD: reflux disease questionnaire, gas-
trointestinal symptom rating scale, and the gastroesophageal
reflux disease impact scale [25, 26]. It consists of 6 questions
related to symptoms and the impact of the disease (sensi-
tivity of 65% and specificity of 71% for GERD diagnosis),
permitting the follow-up of treatments on long-term pa-
tient’s symptoms [27].0e reason why this score was used in
this study, in such scenario, is because a clinical trial with a
unique patient becomes a relevant option.
N-of-1 trials, also known as individual-patient trials or
single-patient trials, are double-blinded, multiple-crossover,
comparative trials of treatment effect [28]. In this study, the
participant is treated with two or more treatments on
multiple occasions during the study, allowing the
identification of the best treatment for each patient [29]. It is
a very useful experimental design for pathologies such as
GERD allowing the efficacy of the individual therapeutic
interventions in this condition; it could be routinely used in
the clinical practice to optimize the PPI treatment for each
patient [30, 31, 32].
0e objective of this study is to compare the efficacy of
standard dose treatment with PPI (esomeprazole 40mg/day)
compared with double dosage (esomeprazole 40mg/bid). It
will be presented as a randomized-controlled single-patient
trial been able to compare two different dosage of PPI
validating the use of double PPI dose to improve the GERD
symptoms in patients with suboptimal therapeutic response
to standard doses of PPI.
2. Methods
2.1. Trial Design. A single-patient trial, placebo-controlled,
randomized, double-blind with 12 pairs of treatment periods
was performed as outpatient at the gastroenterology unit of
the Hospital Universitario Fundación Santa Fe de Bogotá,
Colombia. 0e study was carried out for 24 weeks (from
September 25th, 2012 to April 26th, 2013). 0e study was
approved by the ethics committee from the Hospital Uni-
versitario Fundación Santa Fé de Bogotá (HUFSFB), and the
protocol followed the Helsinki Declaration. Informed
consent was signed by the participant before starting the
study.
2.2. Eligibility Criteria. Patients with the following criteria
were considered eligible: (a) age 18–70 years; (b) heartburn
and/or acid regurgitation on ≥2 days/week for ≥2 months
before the study; (c) partial therapeutic response to a
standard dose of PPIs on ≥2 months of treatment; (d)
impedance-pH monitoring positive for esophageal acid
reflux, DeMeester score greater than 14, absence of alkaline
reflux, and appropriate esophageal emptying; and (e) mental
status allowing us to understand the protocol.
2.3. Exclusion Criteria. 0e participants with the following
criteria were not selected or excluded from this study: (a) a
history of allergies to the medication used in this study; (b)
serious systemic disease, pregnancy, lactation, alarm fea-
tures, motility disorders, or GERD complications; (c) con-
comitant use of other PPIs, histamine H2-receptor
antagonists, prokinetic drugs, herbal medicines, vitamins, or
minerals two weeks before the study; and (d) history of
esophageal or gastric surgery, Schatzki ring, achalasia,
esophageal motility disorders, esophageal candidiasis, or
toxic eosinophilic esophagitis.
2.4. Interventions and Treatments. Patients who presented
GERD symptoms were referred to confirm the diagnosis and
evaluate if they complied with the other requirements to be
part of the study, being exempt from the exclusion criteria.
0e selected patient received two treatments: (A) esome-
prazole 40mg in the morning and night 30minutes before
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meal or (B) esomeprazole 40mg in the morning and placebo
at night 30 minutes before meal. Six different determinations
of treatment were evaluated and 12 pairs of periods of one
week per period (24 weeks) were carried out. Each period
was separated by a washout period of 2 days using alginate
10ml every 12 hours, adding up for a total of 29 weeks of
treatment (see Figure 1).
SPSS was used to randomize the sequence of treatment.
0e medical researchers and the patient were both blind to
this randomized distribution. A pharmaceutical laboratory
provided the medication in 24 boxes, labeled consecutively
from week 1 through 24. Each box contained two blisters
identified as “AM” and “PM,” and each one of the blisters
had 7 identical capsules in texture, color, and taste. 0e
patient was instructed to take the morning (AM) dose 30
minutes before breakfast and the night (PM) dose ap-
proximately 12 hours later.
2.5. Measurements during the Study. 0e efficacy analysis of
the treatment in this study was based on weekly follow-up
evaluations with the GerdQ questionnaire (Table 1). 0e
adherence to treatment was corroborated by performing a
weekly follow-up by asking the patient to register the time
they took the medication every day. Additionally, the par-
ticipant had to return the unused medication to count the
number of nonused capsules. We defined an adequate ad-
herence to the treatments if the patient consumed more than
90% of the capsules.
2.6. StatisticalAnalysis. 0e scores for each pair of treatment
periods were weighed. Exploratory data analysis is applied to
describe the sample. D’agostino–Pearson test was used to
determine if the total scores per treatment were of normal or
nonnormal distribution. Wilcoxon allowed a comparison
between both treatments. ANOVA random factorial II was
applied since the treatments were assigned in a double-blind
randomized study design, covering all the possibilities of
combination of schemes. Finally, Tuckey HSD and box plot
were used to compare the significant differences of the
treatment schemes [32, 33].0e entire significance tests were
performed taking two tails with a CI of 95% and we con-
sidered a significant statistical difference for values of
p< 0.05.
3. Results
0is study included a nonobese 58-year-old man with no
history of tobacco or alcohol consumption and a body mass
index of 26 kg/m2. His endoscopic findings were normal
both for the esophageal mucosa and esophagogastric
junction (EGJ) anatomy. He completed the 12 scheduled
randomized pairs of treatments, and the adherence was
confirmed to be 96% of the treatment.
0e treatment distribution and the scores on the GerdQ
questionnaire obtained are shown in Table 2. Symptomatic
control was similar during both treatments, and scores of
heartburns, regurgitation, stomach pain, nausea, difficulty
sleeping due to heartburns or regurgitation, and rescue
antacid use were also comparable for esomeprazole 40mg/
day or 40mg/bid.
Mean control (±SD) symptoms by treatment A were
found to be 9.5±0.5 and the mean control symptoms by
treatment B were 10.2±0.6, measured on the GerdQ ques-
tionnaire as a high likelihood of having GERD. Mean fre-
quency and severity of each symptom did not significantly
decrease over time (p � 0.30078) (Table 3). 0e behaviors
between the two treatment schemes A and B in the 24 weeks
of the study had no significant difference (Figure 2). 0us,
ANOVA random factorial II showed a significant difference
of symptomatology between the months of study (according
to the combinations handled month by month). However,
there was no significant difference between the two treat-
ments or in the treatment schedule/month relationship.
Since there was a significant difference in the ANOVA
random factorial II, Tuckey HSD and box plot tests were
performed to compare the drug schemes with each variable
of the scale used and the total monthly score. In Figure 3,
scheme B showed a significant difference compared with the
total score (months 1, 3, and 6). However, scheme A did not
present significant differences in the months evaluated.
4. Discussion
Normally randomized controlled trials (RTCs) are the gold
standard for evidence-based practice; however, this provides
a treatment for an average of patients in a trial [34]. N-of-1
trial is used as a very promising tool for patient-centered
outcomes research (PCOR) [35]. 0is type of study is ad-
equate for evaluating long-term treatments for chronic
conditions, and it is not suitable for acute conditions or
diseases. 0e following are required for single-patient trials:
a stable response to treatment, rapid onset of treatment
effect, and negligible expected adverse effects [36].0erefore,
it is a very useful experimental design for pathologies such as
GERD allowing the efficacy of the individual therapeutic
interventions in this condition.
PPIs are widely prescribed for patients with GERD since
they are one of the most potent inhibitors of gastric acid
secretion available [32], thanks to their effectiveness in
treating heartburn and regurgitation symptoms [5]. How-
ever, there is no enough scientific evidence that supports
doubling the dose of PPIs to improve symptomatic control,
compared with the standard dose [14]. 0e findings of this
study confirm showing that doubling the dose of esome-
prazole from 40mg/day to 40mg/bid does not improve
symptomatic control in a patient with GERD.
A significant number of patients in the world treated
with PPIs show a partial response to the treatment due to
heterogeneous character of the illness. PPIs are widely
prescribed; thus, up to 50–70% of these are either un-
necessary or inappropriately prescribed, approximately 113
millions of formulations per year with near 13 billions of
dollars in annual sales [37, 38]. 0erefore, the relevance of
this study is highlighted; it is important for practitioners to
identify patients with a complete response compared to
partial or no-response to treatment [5].
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In this N-of-1 clinical design, increasing the dose of PPI
did not show an improvement of GERD symptoms as the
punctuations of GerdQ questionnaire for both treatments
were similar. 0ere was no significant improvement in the
average frequency and severity of symptoms during the 6
months of study. Regarding additional studies, some clinical
trials report an enhanced efficacy when the PPI dose is
duplicated; however, these results contradict other similar
studies which show no difference between the efficacy for
standard versus double dose of PPI. 0is implies contra-
dictions between different groups of patients and a large
variability of results for different studies.
Cochrane review suggests that doubling the dose of PPI
is associated with larger healing rates for erosive esophagitis
[8]. However, there is no clear dose-symptomatic response
relation for PPIs in erosive esophagitis or NERD [16]. In
0jodleifsson et al.’s study, similar results were obtained; a
multicenter, parallel-group, randomized, double-blind trial
reported no statistically significant difference in the efficacy
rabeprazole 10mg versus 20mg in the for a maintenance
treatment for GERD [18]. In a multicenter, randomized,
double-blind, parallel-group study, analogous results were
obtained; Talley et al. showed esomeprazole 20mg was
superior to placebo as an on-demand treatment for GERD,
though a larger dose of 40mg did not give any clinical benefit
[39]. Finally, in Fass et al.’s study, patients who did not show
symptomatic improvement after an initial therapy using
30mg of lansoprazole once a day were randomized and
separated into two groups for consequent therapy using
either a double dose of lansoprazole or 40mg esomeprazole
once a day; no statistically significant difference was found
[19].
In controversy to the previously discussed studies, an
open-label, randomized, six-way crossover study by Wilder-
Week 1 2 days Week 2 2 days Week 3 2 days Week 4
1 A T B T A T B
Week 5 Week 6 Week 7 Week 8
2 B T B T A T A
Week 9 Week 10 Week 11 Week 12
3 A T A T B T B
Week 13 Week 14 Week 15 Week 16
4 B T A T B T A
Week 17 Week 18 Week 19 Week 20
5 A T B T B T A
Week 21 Week 22 Week 23 Week 24
6 B T A T A T B
Figure 1: Randomization schedule for one patient receiving 12 pairs (n� 24) of treatment, each consisting of one week of treatment A and
one week of treatment B. Abbreviations: A, treatment A (esomeprazole 40mg AM and 40mg PM); B, treatment B (esomeprazole 40mg AM
and placebo PM); T, washout time.
Table 1: 0e GerdQ questionnaire respondent enters the frequency scores after reflecting his/her symptoms over the previous week [27].
Questions/frequency 0 days 1 day 2-3 days 4–7 days
1. How often did you have a burning feeling behind
your breastbone (heartburn)? 0 1 2 3
2. How often did you have stomach contents (liquid
or food) moving upwards to your throat or mouth
(regurgitation)?
0 1 2 3
3. How often did you have pain in the center of the
upper stomach? 3 2 1 0
4. How often did you have nausea? 3 2 1 0
5. How often did you have difficulty getting a good
night of sleep because of your heartburn and/or
regurgitation?
0 1 2 3
6. How often did you take additional medications for
your heartburn and/or regurgitation other than those
your physician told you to take (such as Gaviscon,
Tums, Rolaids, and Maalox)?
0 1 2 3
Scoring information: GerdQ score was calculated as the sum of these scores, giving a total score ranging from 0 to 18. 0ose with a score of 8 or more have a
high likelihood of having gastroesophageal reflux disease (GERD), and those with less than 8 have low or no likelihood.
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Table 2: GerdQ † score for the subject participating in individually evaluable GERD ‡ single-patient trial.
Week Treatment Totalsymptoms (score)
1. Heartburn
(score)
2. Regurgitation
(score)
3. Stomach
pain (score)
4. Nausea
(score)
5. Difficulty sleeping with
heartburn/regurgitation
6. Antacid
use
1 A 12 2 3 0 1 3 3
2 B 11 2 3 0 1 3 2
3 A 12 0 3 1 2 3 3
4 B 13 2 3 1 3 2 2
5 B 11 2 2 1 3 2 1
6 B 5 0 1 1 3 0 0
7 A 7 2 2 0 2 1 0
8 A 10 0 2 3 3 2 0
9 A 6 0 0 3 3 0 0
10 A 10 0 2 3 3 1 1
11 B 8 1 1 3 3 0 0
12 B 10 0 2 3 3 0 2
13 B 10 0 2 3 3 0 2
14 A 10 0 2 3 3 0 2
15 B 12 0 2 3 3 2 2
16 A 8 0 2 3 3 0 0
17 A 10 0 2 3 3 0 2
18 B 12 0 2 3 3 2 2
19 B 9 0 2 3 3 0 1
20 A 10 0 2 3 3 0 2
21 B 10 0 0 3 3 2 2
22 A 10 0 2 3 3 0 2
23 A 9 0 1 3 3 0 2
24 B 11 0 2 3 3 1 2
A: treatment A (esomeprazole 40mgAM and 40mg PM); B: treatment B (esomeprazole 40mgAM and placebo PM). †GerdQ: gastroesophageal reflux disease
questionnaire. ‡GERD: gastroesophageal reflux disease.
Table 3: Results for treatment comparisons of the N-of-1 trial (12 pairs of treatments, 24 weeks).
Weeks of
treatment
Mean-controlled symptoms
(GerdQ)
Standard
deviation D’Agostino–Pearson
Wilcoxon test p
value
Treatment A
(±SD) 12 9.50 0.5 0.598 0.30078
Treatment B
(±SD) 12 10.17 0.6 0.035
†GerdQ: gastroesophageal reflux disease questionnaire.
4
5
6
7
8
9
10
11
12
13
14
1 2 3 4 5 6 7 8 9 10 11 12
Sc
or
e
Weeks
Wilcoxon p = 0.3
Performance of the treatment schemes A and B
A
B
Figure 2: Performance of the treatment schemes A and B according to the total score of the GerdQ scale in the 12 weeks of treatment.
Abbreviations: A: treatment A (esomeprazole 400mg AM and 40mg PM); B: treatment B (esomeprazole 40mg AM and placebo PM).
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Smith et al. [17] showed an improvement over acid control
in patients with GERD when increasing the dose of oral
esomeprazole (20mg, 40mg, and 80mg) and pantoprazole
(40mg and 80mg). Another similar study reports a sig-
nificant symptomatic improvement in pediatric population
when using 20 versus 40mg of pantoprazole [40]. Finally, a
third open-label, single-center, randomized, six-way cross-
over study over 40 healthy subjects receiving esomeprazole
20, 40, and 80mg and lansoprazole 15, 30, and 60mg once
daily for 5 days showed that increasing the dose of eso-
meprazole and lansoprazole improved significantly the
control of acids [41].
0e results of this study suggest that considering healthy
lifestyles and healthy patients could have a low impact over
the partial response to PPI treatment albeit the data available
in the literature about the influence of lifestyle over reflux
symptoms are inconsistent [42–45]. Moreover, it has been
implied that adherence to treatment problems could play a
role in the partial response to PPIs, yet this was not observed
in our study. In Ruigómez et al. study [46], females tend to be
more susceptible to a partial response to PPI therapy, but
neither age, overweight, obesity, tobacco, nor alcohol usage
were associated with an increased risk towards a partial
response to PPIs. Likewise, polimedicated patients, those
who show anxiety or depression signs, those with an initial
diagnose of esophagus cancer or severe GERD, presented a
higher risk of not responding completely to the PPI-based
therapy.
0is N-of-1 trial could be useful to avoid unnecessary
clinical conducts like duplicating the dose of PPI in many
patients diagnosed with GERD.0e aim of this clinicalN-of-
1 trial is to provide scientific evidence that may lead to
eliminating unnecessary doubling of PPI dosage. 0us, we
recommend more N-of-1 trials in the GERD field due to
their potential value as systematic methods that evaluate
therapies without strong scientific evidence; performing N-
of-1 trials, contemplating other GERD phenotypes, and
testing different PPI dosages would be interesting for further
studies. Furthermore, N-of-1 trials can be used for com-
paring a wide range of therapies for many gastroentero-
logical diseases, while providing individual-focused
outcomes, the combinedN-of-1 trial design offers promising
bridging between research and clinical practice.
0is study has several strengths: 1. the doses investigated
were the same as those used in clinical practice; 2. the study
was performed in a patient in whom our approach was
clearly applicable; 3. at the end of the study, the patient
reported a better understanding of his illness (GERD) due to
his involvement in the results of the study; 4. any possible
correlation between 7-day periods was eliminated by in-
cluding a two-day washout period; and 5. the large number
of observation periods (12 pairs of treatment periods, sample
size) increased the statistical significance of the results and
reduced the risk for false inferences or shadowing.
0e limitations of this study were 1. being a single-pa-
tient trial, the findings can be nonrepresentative for other
groups of patients; 2. a healthy patient was selected com-
pared to regular clinical practice patients with obesity,
different comorbidities, polypharmacy, usage of tobacco or
alcohol, and so on; 3. a close follow-up process was per-
formed during the 24 weeks of treatment, including weekly
medical visits and phone calls to obtain adequate adherence
to the therapy; and 4. a potentially memory bias could be
present given the high-frequency reply to the GerdQ every
week; one month is the time frame which ensures a good
balance between education of recall bias and having ap-
propriate information on outcome measures [47].
Evidence-based medicine suggests that clinicians should
rely on the results of randomized controlled trials (RCTs)
over groups of patients; however, even when relevant RCTs
generate a probable answer, their results may not apply to a
given individual patient. 0us, N-of-1 trials are an oppor-
tunity for tailor treatments to individual patients consid-
ering that these trials are at the top of the hierarchy in terms
of strength of evidence for treatment decisions [48]. Also,
patients appear to benefit from the participation in such
trials given their improved sense of involvement and control
over their treatments, as well as an increase in care focused
on the individual, which is not commonly available in the
routines of clinical practice.
0erefore, investing and increasing the frequency of use
of N-of-1 trials is expected to be a positive factor in pro-
gressing towards patient-centered care and shared decision-
making in clinical practice [49]. Clinicians can incorporate
the N-of-1 RCTs into their medical practice for determining
the optimum treatment of a given individual patient. Lastly,
the N-of-1 approach clearly has the potential of improving
the quality of medical care in patient with chronic diseases.
0is is definitely an innovative patient-centered approach to
drug management [50].
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6
Month
6
8
10
12
Total score (GerdQ): month-treatment scheme
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B
Figure 3: Measurement of total scale (GerdQ) per month of
treatment: comparison between schemes A and B. (Tuckey HSD).
Abbreviations: A: treatment A (esomeprazole 40mg AM and 40mg
PM); B: treatment B (esomeprazole 40mg AM and placebo PM).
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In conclusion, there was no significant improvement in
the patient GERD symptoms increasing the dose of oral
esomeprazole during the 6 months of study. N-of-1 trials in
chronic pathologies including GERD are recommended due
to their potential value as systematic methods that evaluate
therapies without strong scientific evidence.
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PPIs: Proton pump inhibitors
GERD: Gastroesophageal reflux disease
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RCTs: Randomized clinical trials
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[46] A. Ruigómez, S. Johansson, B. Wernersson, O. Fernández
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